Document:

EX-4.5

 Exhibit 4.5 

In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which
the omitted executed warrants differ from the form of warrant that follows: 
  

			
	 	 	Number of Shares
		 	157,526
		 	105,017

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF
LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	Company:	  	ACUTUS MEDICAL, INC., a Delaware corporation
		
	Number of Shares:	  	[105,017 / 157,526] (Subject to Section 1.7)
		
	Type/Series of Stock:	  	Series C Preferred (Subject to Section 1.7)
		
	Warrant Price:	  	$1.714 per share (Subject to Section 1.7)
		
	Issue Date:	  	July 31, 2018
		
	Expiration Date:	  	July 31, 2028 See also Section 5.1(b).
		
	Credit Facility:	  	This Warrant to Purchase Stock (“Warrant”) is issued in connection with that certain Loan and Security Agreement of even date herewith among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time
to time party thereto, and the Company (as modified, amended and/or restated from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, OXFORD FINANCE LLC
(“Oxford” and, together with any successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant
Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 

SECTION 1.    EXERCISE. 

1.1    Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part,
by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix I and, unless Holder is exercising this Warrant pursuant to a cashless exercise set
forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares
being purchased. 
 1.2    Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the
aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or portion hereof as to which
this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula: 

					
		  	X = Y(A-B)/A
			
	 where:
	  		  	
			
		  	X =	  	the number of Shares to be issued to the Holder;
			
		  	Y =	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
			
		  	A =	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
			
		  	B =	  	the Warrant Price.

 1.3    Fair Market Value. If the Company’s common stock is then traded or
quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading Market”) and the
Class is common stock, the fair market value of a Share shall be the closing price or last sale price of a share of common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its
Notice of Exercise to the Company. If the Company’s common stock is then traded in a Trading Market and the Class is a series of the Company’s convertible preferred stock, the fair market value of a Share shall be the closing price or
last sale price of a share of the Company’s common stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together with its Notice of Exercise to the Company multiplied by the number of shares of
the Company’s common stock into which a Share is then convertible. If the Company’s common stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable
good faith judgment. 
 1.4    Delivery of Certificate and New Warrant. Within a reasonable time after Holder
exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not been fully exercised and has
not expired, a new warrant of like tenor representing the Shares not so acquired. 
 1.5    Replacement of
Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant
of like tenor and amount. 
 1.6    Treatment of Warrant Upon Acquisition of Company. 

(a)    Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series
of related transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company (ii) any merger or consolidation of the Company into or with another person or entity
(other than a merger or consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger,
consolidation or reorganization, own les s than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders
beneficially own a majority of the outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or
other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

(b)    Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be
received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), either (i) Holder shall exercise

  
 2 

 
this Warrant pursuant to Section 1.1 and/or 1.2 and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition or (ii) if
Holder elects not to exercise the Warrant, this Warrant will expire immediately prior to the consummation of such Acquisition. 

(c)    The Company shall provide Holder with written notice of its request relating to the Cash/Public Acquisition
(together with such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such contemplated Cash/Public Acquisition giving rise to such notice), which is to be delivered to Holder not less
than seven (7) Business Days prior to the closing of the proposed Cash/Public Acquisition. In the event the Company does not provide such notice, then if, immediately prior to the Cash/Public Acquisition, the fair market value of one Share (or
other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be
exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall promptly notify the Holder of the number of Shares (or such other securities)
issued upon such exercise to the Holder and Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof. 

(d)    Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or
successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of
this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(e)    As used in this Warrant, “Marketable Securities” means securities meeting all of the following
requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its
filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to
exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all
of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such
restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six (6) months from the closing of such Acquisition. 

1.7    Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative.
Upon the closing of the Next Equity Financing, the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant and the
“Warrant Price” shall be the lower of the Warrant Price then in effect and the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant;
provided, that upon such date, if any, if the Warrant Price is changed to the Next Equity Financing pursuant to this sentence, this Warrant shall be exercisable for such number of shares of such Class as shall equal (i) One Hundred Eighty
Thousand Dollars ($180,000.00), divided by (ii) the Next Equity Financing Price, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. As used herein (i) “Next Equity Financing” means
the first sale or issuance by the Company on or after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its convertible preferred stock or other senior equity securities to one or
more investors for cash for financing purposes; (ii) “Next Equity Financing Securities” means the type, class and series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Equity
Financing; and (iii) “Next Equity Financing Price” means the lowest price per share for which Next Equity Financing Securities are sold or issued by the Company in the Next Equity Financing. 

  
 3 

 SECTION 2.    ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 2.1    Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the
outstanding shares of the Class payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number
and kind of securities and property which Holder would have received bad Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Class by reclassification
or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2    Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding
shares of the Class are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be
exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3    Conversion of Preferred Stock. If the Class is a class and series of the Company’s convertible
preferred stock, in the event that all outstanding shares of the Class are converted, automatically or by action of the holders thereof, into common stock pursuant to the provisions of the Company’s Certificate of Incorporation, including,
without limitation, in connection with the Company’s initial, underwritten public offering and sale of its common stock pursuant to an effective registration statement under the Act (the “IPO”), then from and after the date on
which all outstanding shares of the Class have been so converted, this Warrant shall be exercisable for such number of shares of common stock into which the Shares would have been converted had the Shares been outstanding on the date of such
convers ion, and the Warrant Price shall equal the Warrant Price in effect as of immediately prior to such conversion divided by the number of shares of common stock into which one Share would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. 
 2.4    Adjustments for Diluting
Issuances. Without duplication of any adjustment otherwise provided for in this Section 2, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the
manner set forth in the Company’s Articles or Certificate of Incorporation as if the Shares were issued and outstanding on and as of the date of any such required adjustment. 

2.5    No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of
Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by
multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6    Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of
Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, Class and/or number of Shares and facts upon which such adjustment is based. The
Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and number of Shares in effect upon the date of such
adjustment. 

  
 4 

 SECTION 3.     REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 3.1    Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as
follows: 
 (a)    The initial Warrant Price referenced on the first page of this Warrant is not greater than the price
per share at which shares of the Class were last sold and issued prior to the Issue Date hereof in an arms-length transaction in which at least $500,000 of such shares were sold. 

(b)    All Shares which may be issued upon the exercise of this Warrant, and all securities, if any, issuable upon
conversion of the Shares, shall, upon issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein
or under applicable federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of shares of the Class, common stock and
other securities as will be sufficient to permit the exercise in full of this Warrant and the conversion of the Shares into common stock or such other securities. 

(c)    The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material
respects, as of the Issue Date. 
 3.2    Notice of Certain Events. If the Company proposes at any time to: 

(a)    declare any dividend or distribution upon the outstanding shares of the Class or common stock, whether in
cash, property, stock, or other securities and whether or not a regular cash dividend; 
 (b)    offer for subscription
or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 (c)    effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the
outstanding shares of the Class; 
 (d)    effect an Acquisition or to liquidate, dissolve or wind up; or 

(e)    effect an IPO; 

then, in connection with each such event, the Company shall give Holder: 

(1)    at least seven (7) Business Days prior written notice of the date on which a record will be taken for such
dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining rights to vote, if any, in respect of the matters referred to in
(a) and (b) above; 
 (2)    in the case of the matters referred to in (c) and (d) above at least seven
(7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their shares for the securities or other
property deliverable upon the occurrence of such event); and 
 (3)    with respect to the IPO, at least seven
(7) Business Days prior written notice of the date on which the Company proposes to file its registration statement in connection therewith. 

Reference is made to Section 1.6(c) whereby this Warrant will be deemed to be exercised pursuant to Section 1.2 hereof if the Company does not give
written notice to Holder of a Cash/Public Acquisition as required by the terms hereof. Company will also provide information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting
requirements. 

  
 5 

 SECTION 4.    REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by
Holder are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the
specific purpose of acquiring this Warrant or the Shares. 
 4.2    Disclosure of Information. Holder is aware of
the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant
and its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. Holder bas experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying
securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business
relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4    Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Act. 
 4.5    The Act. Holder understands that this Warrant and the Shares issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption there from, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder
understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or un less exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6    Market Stand-off Agreement. The Holder agrees that the Shares shall
be subject to the Market Standoff provisions in Section [                    ] of the Investor Rights Agreement or similar agreement. 

4.7    No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of
this Warrant. 
 SECTION 5.    MISCELLANEOUS. 

5.1    Term; Automatic Cashless Exercise Upon Expiration. 

(a)    Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at
any time and from time to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter. 

(b)    Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market
value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall

  
 6 

 
automatically be deemed on and as of such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been
exercised, and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued upon such exercise to Holder. 

5.2    Legends. Each certificate evidencing Shares (and each certificate evidencing the securities issued upon
conversion of any Shares, if any) shall be imprinted with a legend in substantially the following form: 
 THE SHARES EVIDENCED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO OXFORD
FINANCE LLC DATED JULY 31, 2018, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER,
SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 
 5.3    Compliance with Securities Laws on
Transfer. This Warrant and the Shares issued upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance
with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably
requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D
promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4    Transfer Procedure. After receipt by Oxford of the executed Warrant, Oxford may transfer all or part of this
Warrant to one or more of Oxford’s affiliates (each an “Oxford Affiliate”), by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing the Company with
written notice, Oxford, any such Oxford Affiliate and any subsequent Holder, may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the Shares issuable directly or indirectly, upon conversion of the Shares,
if any) to any other transferee, provided however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and
taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). Notwithstanding any contrary provision here in, at all times prior to the IPO,
Holder may not, without the Company’s prior written consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any
exercise hereof, to any person or entity who directly competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5    Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall
be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or
electronic mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished
to the Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives
notice of a change of address in connection with a transfer or otherwise: 

  
 7 

 Oxford Finance LLC 

133 N. Fairfax Street 

Alexandria, VA 22314 
 Attn:
Legal Department 
 Telephone: ([        ])
[        -        ] 
 Facsimile:
([        ]) [        -        ] 

Email:
[                                @         
           .        ] 
 Notice to the Company
shall be addressed as follows until Holder receives notice of a change in address: 
 ACUTUS MEDICAL, INC. 

2210 Faraday Avenue 
 Suite 100

 Carlsbad, CA 92008 
 Attn:
[                            ] 

Fax: ([        ])
[        -        ] 
 Email:
[                                @         
           .        ] 
 With a copy (which
shall not constitute notice) to: 
 Wilson Sonsini Goodrich & Rosati 

650 Page Mill Road 
 Palo Alto,
CA 94304 
 Attn:
[                            ] 

Email:
[                                @         
           .        ] 

5.6    Waiver. This Warrant and any term hereof may be changed, waived discharged or terminated (either generally
or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any
amendment thereto. 
 5.9    Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of California, without giving effect to its principles regarding conflict of law. 

5.10    Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise
affect the meaning of any provision of this Warrant. 
 5.11    Business Days. “Business Day” is
any day that is not a Saturday Sunday or a day on which Oxford is closed. 
 [Remainder of page left blank intentionally] 

[Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ACUTUS MEDICAL, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
		
	Title:	 	  

  
 [Signature Page to
Warrant to Purchase Stock] 

 IN WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by
their duly authorized representatives effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ACUTUS MEDICAL, INC.
		
	By:	 	
                     
                    

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	OXFORD FINANCE LLC
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  
 [Signature Page to
Warrant to Purchase Stock] 

 APPENDIX 1 

  
 Appendix 1 

 APPENDIX 2 

  
 Appendix 2 

 SCHEDULE 1EX-4.6

 Exhibit 4.6 

In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the
omitted executed warrants differ from the form of warrant that follows: 
  

					
	Holder	  	 	 
	OrbiMed Royalty Opportunities II, LP	  			
	Deerfield Private Design Fund III, L.P.	  			

 THIS WARRANT AND THE SECURITIES PURCHASABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF
1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE. 

ACUTUS MEDICAL, INC. 

WARRANT 
 dated as of
May 20, 2019 (the “Issue Date”) 
 THIS CERTIFIES THAT, for value received, [OrbiMed Royalty Opportunities II,
LP / Deerfield Private Design Fund III, L.P.] or its successors or permitted assigns (such Person and such successors and assigns each being the “Warrant Holder” with respect to the Warrant held by it), at any time and from
time to time on any Business Day on or prior to 5:00 p.m. (New York City time), on the Expiration Date (as herein defined), is entitled (a) to subscribe for the purchase from Acutus Medical, Inc., a Delaware corporation (the
“Company”), 2,042,007 Shares at a price per Share equal to the Exercise Price (as herein defined), and (b) to the other rights set forth herein; provided that the number of Shares issuable upon any exercise of
this Warrant and the Exercise Price shall be adjusted and readjusted from time to time in accordance with Section 5. By accepting delivery hereof, the Warrant Holder agrees to be bound by the provisions hereof. 

IN FURTHERANCE THEREOF, the Company irrevocably undertakes and agrees for the benefit of Warrant Holder as follows: 

Section 1.    Definitions and Construction. 

(a)    Certain Definitions. As used herein (the following definitions being applicable in both singular and plural
forms): 
 “Affiliate” means, with respect to any Person, any other Person that directly or indirectly controls, is
controlled by, or is under common control with such Person. 

 “Appraised Value” means at any time the fair market value thereof
determined in good faith by the board of directors of the Company as of a date which is within ten (10) days of the date as of which the determination is to be made, subject to the rights of the Requisite Holders pursuant to Section 5(l).

 “Business Day” means any day except a Saturday, Sunday or other day on which commercial banks in New York City,
New York or Carlsbad, California are authorized by law to close. 
 “Closing Price” means, for any trading day with
respect to a Share, (a) the last reported sale price on such day on the principal national securities exchange on which the Shares are listed or admitted to trading or, if no such reported sale takes place on any such day, the average of the
closing bid and asked prices thereon, as reported in The Wall Street Journal or (b) if such Shares shall not be listed or admitted to trading on a national securities exchange, the last reported sales price on the NASDAQ National Market
System or, if no such reported sale takes place on any such day, the average of the closing bid and asked prices thereon, as reported in The Wall Street Journal, or (c) if such Shares shall not be quoted on such National Market System
nor listed or admitted to trading on a national securities exchange, then the average of the closing bid and asked prices, as reported by The Wall Street Journal for the
over-the-counter market; provided that if clause (a), (b), or (c) applies and no price is reported in The Wall Street
Journal for any trading day, then the price reported in The Wall Street Journal for the most recent prior trading day shall be deemed to be the price reported for such trading day. 

“Commission” means the Securities and Exchange Commission or any other Federal agency administering the Securities Act
at the time. 
 “Credit Agreement” means the Credit Agreement dated as of the date hereof by and among the Company,
the lenders from time to time party thereto, Wilmington Trust, National Association, and Orbimed Royalty Opportunities II, LP. 

“Exchange Act” means the Securities Exchange Act of 1934, or any successor Federal statute, and the rules and
regulations of the Commission thereunder, all as the same shall be in effect at the time. 
 “Exercise Amount” means
for any number of Warrant Shares as to which this Warrant is being exercised the product of (i) such number of Warrant Shares times (ii) the Exercise Price. 

“Exercise Price” means $1.714 per Share, as adjusted from time to time pursuant to Section 5. 

“Expiration Date” means May 20, 2029. 

“Initial Holder” means [OrbiMed Royalty Opportunities II, LP / Deerfield Private Design Fund III, L.P.] 

“Market Price” on any day means (a) the volume weighted average price of the daily Closing Prices per Share for
the 20 consecutive trading days prior to such date or (b) if clauses (a), (b) and (c) of the definition of “Closing Price” are inapplicable, then the Appraised Value as of such day shall apply. 

“Person” means an individual, a corporation, a partnership, an association, a trust or any other entity or
organization, including a government or political subdivision or an agency or instrumentality thereof. 
 “Requisite
Holders” means at any time holders of Warrant Shares and Warrants representing at least a majority of the Warrant Shares outstanding or issuable upon the exercise of all the outstanding Warrants. 

  
 2 

 “Securities Act” means the Securities Act of 1933, or any successor
Federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Shares” means, subject to Section 5(b), the Company’s currently authorized Series C preferred stock (the
“Class”), $0.001 par value, and stock of any other class or other consideration into which such currently authorized capital stock may hereafter have been changed. 

“Warrant” means, as the context requires, this warrant and any successor warrant or warrants issued upon a whole or
partial transfer or assignment of any such warrant or of any such successor warrant. 
 “Warrant Shares” means the
number of Shares issued or issuable upon exercise of this Warrant as set forth in the introduction hereto, as adjusted from time to time pursuant to Section 5, or in the case of other Warrants, issuable upon exercise of
those Warrants. 
 (b)    Accounting Terms and Determinations. Unless otherwise specified herein, all accounting
terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be delivered hereunder shall be prepared, in accordance with generally accepted accounting principles. When used
herein, the term “financial statements” shall include the notes and schedules thereto. References to fiscal periods are to fiscal periods of the Company. 

(c)    Computation of Time Periods. With respect to the computation of periods of time from a specified date to a
later specified date, the word “from” means “from and including” and the words “to” and “until” each mean “to but excluding.” Periods of days shall be counted in calendar days unless otherwise
stated. 
 (d)    Construction. Unless the context requires otherwise, references to the plural include the
singular and to the singular include the plural references to any gender include any other gender, the part includes the whole, the term “including” is not limiting, and the term “or” has, except where otherwise indicated, the
inclusive meaning represented by the phrase “and/or.” The words “hereof,” “herein,” “hereby,” “hereunder,” and similar terms in this Warrant refer to this Warrant as a whole and not to any particular
provision of this Warrant. Section, subsection, clause, exhibit and schedule references are to this Warrant, unless otherwise specified. Any reference to this Warrant includes any and all permitted alterations, amendments, changes, extensions,
modifications, renewals or supplements thereto or thereof: as applicable. 
 (e)    Exhibits and
Schedules. All of the exhibits and schedules attached hereto shall be deemed incorporated herein by reference. 

(f)    No Presumption Against Any Party. Neither this Warrant nor any uncertainty or ambiguity herein or therein
shall be construed or resolved using any presumption against any party hereto or thereto, whether under any rule of construction or otherwise. On the contrary, this Warrant has been reviewed by each of the parties and their counsel and, in the case
of any ambiguity or uncertainty, shall be construed and interpreted according to the ordinary meaning of the words used so as to fairly accomplish the purposes and intentions of all parties hereto. 

Section 2.    Exercise of Warrant. 

(a)    Exercise and Payment. The Warrant Holder may exercise this Warrant in whole or in part, at any time or from
time to time on any Business Day on or prior to the Expiration Date, by delivering to the Company a duly executed notice (a “Notice of Exercise”) in the form of Exhibit A and

  
 3 

 
by payment to the Company of the Exercise Price per Warrant Share, at the election of the Warrant Holder, either (a) by wire transfer of immediately available funds to the account of the
Company in an amount equal to the Exercise Amount, (b) if the Closing Price as of the trading day immediately prior to the date of such exercise is greater than the Exercise Price, then by receiving from the Company the number of Warrant Shares
equal to (i) the number of Warrant Shares as to which this Warrant is being exercised minus (ii) the number of Warrant Shares having a value, based on the Closing Price on the trading day immediately prior to the date of such exercise (or
if there is no such Closing Price, then based on the Appraised Value as of such day), equal to the Exercise Amount, or (c) any combination of the foregoing. The Company acknowledges that the provisions of clause (b) are intended, in part,
to ensure that a full or partial exchange of this Warrant pursuant to such clause (b) will qualify as a conversion, within the meaning of paragraph (d)(3)(iii) of Rule 144 under the Securities Act. At the request of any Holder, the Company will
accept reasonable modifications to the exchange procedures provided for in this Section in order to accomplish such intent. For all purposes of this Warrant (other than this Section 2(a)), any reference herein to the
exercise of this Warrant shall be deemed to include a reference to the exchange of this Warrant into Shares in accordance with the terms of clause (b). 

(b)    Effectiveness and Delivery. As soon as practicable but not later than five (5) Business Days after the
Company shall have received such duly completed Notice of Exercise and payment in full for the number of Warrant Shares so being exercised, the Company shall execute and deliver or cause to be executed and delivered, in accordance with such Notice
of Exercise, a certificate or certificates representing the number of Shares specified in such Notice of Exercise, issued in the name of the Warrant Holder or in such other name or names of any Person or Persons designated in such Notice of
Exercise. This Warrant shall be deemed to have been exercised and such Share certificate or certificates shall be deemed to have been issued, and the Warrant Holder or other Person or Persons designated in such Notice of Exercise shall be deemed for
all purposes to have become a holder of record of Shares, alias of the date that such Notice of Exercise and payment shall have been received by the Company. 

(c)    Surrender of Warrant. The Warrant Holder shall surrender this Warrant to the Company when it delivers the
Notice of Exercise, and in the event of a partial exercise of the Warrant, the Company shall execute and deliver to the Warrant Holder, at the time the Company delivers the Share certificate or certificates issued pursuant to such Notice of
Exercise, a new Warrant for the unexercised portion of the Warrant, but in all other respects identical to this Warrant. 

(d)    Legend. Each certificate for Warrant Shares issued upon exercise of this Warrant, unless at the time of
exercise such Warrant Shares are registered under the Securities Act, shall bear the following legend: 
 THIS SECURITY HAS NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933 AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS, UNLESS AN EXEMPTION FROM
SUCH REGISTRATION IS AVAILABLE. 
 Any certificate for Warrant Shares issued at any time in exchange or substitution for any certificate
bearing such legend (unless at that time such Warrant Shares are registered under the Securities Act) shall also bear such legend unless, in the written opinion of counsel selected by the holder of such certificate (who may be an employee of such
holder), which counsel and opinion shall be reasonably acceptable to the Company, the Warrant Shares represented thereby need no longer be subject to restrictions on resale under the Securities Act. 

  
 4 

 (e)    Fractional Shares. The Company shall not be required to
issue fractions of Shares upon an exercise of the Warrant. If any fraction of a Share would, but for this restriction, be issuable upon an exercise of the Warrant, in lieu of delivering such fractional Share, the Company shall pay to the Warrant
Holder, in cash, an amount equal to the same fraction times the Closing Price on the trading day immediately prior to the date of such exercise (or if there is no such Closing Price, then based on the Appraised Value as of such day). 

(f)    Expenses and Taxes. The Company shall pay all expenses, taxes and owner charges payable in connection with
the preparation, issuance and delivery of certificates for the Warrant Shares and any new Warrants, except that if the certificates for the Warrant Shares or the new Warrants are to be registered in a name or names other than the name of the Warrant
Holder, funds sufficient to pay all transfer taxes payable as a result of such transfer shall be paid by the Warrant Holder at the time of its delivery of the Notice of Exercise or promptly upon receipt of a written request by the Company for
payment. 
 (g)    Automatic Cashless Exercise. To the extent that there has not been an exercise by the Warrant
Holder pursuant to Section 2(a) hereof, and provided that the Closing Price (or if there is no such Closing Price, then based on the Appraised Value as of such day) as of the trading day immediately prior to the date of such exercise exceeds
the Exercise Price on the Expiration Date, then any portion of the Warrant that remains unexercised shall be exercised automatically in whole (not in part), upon the Expiration Date. Provided that the Closing Price (or if there is no such Closing
Price, then based on the Appraised Value as of such day) as of the trading day immediately prior to the date of such exercise exceeds the Exercise Price on the Expiration Date, then payment by the Warrant Holder upon such automatic exercise shall be
in the form of the Warrant Holder receiving from the Company the number of Warrant Shares equal to (i) the number of Warrant Shares as to which this Warrant is being automatically exercised minus (ii) the number of Warrant Shares having a
value, based on the Closing Price as of the trading day immediately prior to the date of such automatic exercise (or if there is no such Closing Price, then based on the Appraised Value as of such day), equal to the Exercise Amount. 

Section 3.    Investment Representation. By accepting the Warrant, the Warrant Holder represents that it is
acquiring the Warrant for its own account for investment purposes and not with the view to any sale or distribution, that the Warrant Holder will not offer, sell or otherwise dispose of the Warrant or the Warrant Shares except under circumstances as
will not result in a violation of applicable securities laws, and that the Warrant Holder is an “accredited investor” as that term is defined in Rule 501 under the Securities Act. The Warrant Holder further represents and warrants that
(i) it understands that the Warrant or the Warrant Shares has not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act the availability of which
depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Holder’s representations as expressed herein or otherwise made pursuant hereto; (ii) it understands and acknowledges that no
public market now exists for any of the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities; (iii) it has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating the merits and risks of its investment in the
Company and protecting its own interests; and (iv) it is aware of the Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an
informed decision with respect to the acquisition of the Warrant or the Warrant Shares. 

Section 4.    Validity of Warrant and Issuance of Shares. 

  
 5 

 (a)    The Company represents and warrants that this Warrant has been
duly authorized, is validly issued, and constitutes the valid and binding obligation of the Company. 
 (b)    The
Company further represents and warrants that on the date hereof it has duly authorized and reserved, and the Company hereby agrees that it will at all times until the Expiration Date have duly authorized and reserved, such number of Shares as will
be sufficient to permit the exercise in full of the Warrant, and that all such Shares are and will be duly authorized and, when issued upon exercise of the Warrant, will be validly issued, fully paid and
non-assessable, and free and clear of all security interests, claims, liens, equities and other encumbrances. 

Section 5.    Warrant Shares; Antidilution Provisions. The Exercise Price in effect at any time, and the
number of Warrant Shares that may be purchased upon any exercise of the Warrant, shall be subject to change or adjustment as follows: 

(a)    Share Split; Share Reclassification. If the Company shall subdivide its outstanding Shares into a greater
number of Shares, by way of a stock split, stock dividend or otherwise, or consolidate its outstanding Shares into a smaller number of Shares (any such event being herein called a “Share Split”), then (i) the Exercise
Price shall be adjusted, effective immediately after the effective date of such Share Split, to a price determined by multiplying the Exercise Price in effect immediately prior to such effective date by a fraction, the numerator of which shall be
the number of Shares outstanding on such effective date before giving effect to such Share Split and the denominator of which shall be the number of Shares outstanding after giving effect to such Share Split, and (ii) the number of Shares
subject to purchase upon exercise of this Warrant shall be adjusted, effective at such time, to a number determined by multiplying the number of Shares subject to purchase immediately before such Share Split by a fraction, the numerator of which
shall be the number of Shares outstanding after giving effect to such Share Split and the denominator of which shall be the number of Shares outstanding immediately before giving effect to such Share Split. 

If the Shares issuable upon exercise of the Warrant are changed into the same or a different number of securities of any other class or
classes by reclassification, capital reorganization, or a conversion of all outstanding shares of the relevant class or series, or otherwise, including through a conversion of all outstanding shares of the relevant class or series into shares of
Common Stock upon an initial public offering of the Company’s securities (a “Share Reclassification”), then, in any such event, in lieu of the number of Shares which the Holder would otherwise have been entitled to
receive, the Holder shall have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder of the number of securities deliverable upon exercise of this Warrant immediately before that
change would have been entitled to receive in such Share Reclassification, all subject to further adjustment as provided herein with respect to such other shares. 

(b)    Adjustment to Class of Shares; Number of Shares; Warrant Price; Adjustments Cumulative.
Upon the closing of the Next Equity Financing, the “Class” shall be Next Equity Financing Securities from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant and the
“Exercise Price” shall be the lower of the Exercise Price then in effect and the Next Equity Financing Price from and after such closing, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant;
provided, that upon such date, if any, if the Exercise Price is changed to the Next Equity Financing Price pursuant to this sentence, this Warrant shall be exercisable for such number of shares of such Class as shall equal (i) three
million and five hundred thousand Dollars ($3,500,000.00), divided by (ii) the Next Equity Financing Price, subject to adjustment thereafter from time to time in accordance with the provisions of this Warrant. As used herein (i)
“Next Equity Financing” means the first sale or issuance by the Company on or after the Issue Date of this Warrant set forth above, in a single transaction or series of related transactions, of shares of its

  
 6 

 
convertible preferred stock or other senior equity securities to one or more investors for cash for financing purposes for aggregate gross proceeds of at least $23,000,000 (excluding all proceeds
from the conversion of any convertible promissory notes or cancellation of convertible promissory notes in consideration for the issuance of preferred stock); (ii) “Next Equity Financing Securities” means the type, class and
series of convertible preferred stock or other senior equity security sold or issued by the Company in the Next Equity Financing; and (iii) “Next Equity Financing Price” means the lowest cash price per share for which Next
Equity Financing Securities are sold or issued by the Company in the Next Equity Financing. 
 (c)    Special
Distributions. If the Company shall issue or distribute to any holder or holders of Shares evidences of indebtedness, any other securities of the Company or any cash, property or other assets (excluding a Share Split or Share Classification),
whether or not accompanied by a purchase, redemption or other acquisition of Shares (any such nonexcluded event being herein called a “Special Distribution”), then the Warrant Holder shall be entitled to a pro-rata Share of such Special Distribution as though the Warrant Holder had fully exercised this Warrant immediately prior to the record date for such Special Distribution, and the Company shall pay or distribute
such pro-rata share to Warrant Holder when paid or distributed to the holders of the Shares, or the Warrant Holder may at its option decline to accept such payment or distribution in which case the
(x) the Exercise Price shall be decreased, effective immediately after the effective date of such Special Distribution, to a price determined by multiplying the Exercise Price then in effect by a fraction, the numerator of which shall be the
Market Price immediately prior to such effective date less any cash and the then fair market value, as determined in good faith by the board of directors of the Company, of any evidences of indebtedness, securities or property or other assets issued
or distributed in such Special Distribution with respect to one Share, and the denominator of which shall be the Market Price immediately prior to such effective date, and (y) the number of Shares subject to purchase upon exercise of this
Warrant shall be increased to a number determined by multiplying the number of Shares subject to purchase immediately before such Special Distribution by a fraction, the numerator of which shall be the Exercise Price in effect immediately before
such Special Distribution and the denominator of which shall be the Exercise Price in effect immediately after such Special Distribution. 

(d)    Corporate Reorganization. Without limiting any of the other provisions hereof, if any (i) capital
reorganization; (ii) reclassification of the capital stock of the Company; (iii) merger, consolidation or reorganization or other similar transaction or series of related transactions which results in the voting securities of the Company
outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 50% of the combined voting power of the voting
securities of or economic interests in the Company or such surviving or acquiring entity outstanding immediately after such merger, consolidation or reorganization; (iv) sale, lease, license, transfer, conveyance or other dis position of all or
substantially all of the assets of the Company; (v) sale of shares of capital stock of the Company, in a single transaction or series of related transactions, representing at least 50% of the voting power of the voting securities of or economic
interests in the Company; or (vi) the acquisition by any “person” (together with his, her or its Affiliates) or “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) acquires, directly or
indirectly, the beneficial ownership (as such term is defined in Rule 13d-3 promulgated under the Exchange Act) of outstanding shares of capital stock and/or other equity securities of the Company, in a single
transaction or series of related transactions (including, without limitation, one or more tender offers or exchange offers), representing at least 50% of the voting power of or economic interests in the then outstanding shares of capital stock of
the corporation (each of (i)–(vi) above a “Corporate Reorganization”) shall be effected, then the Company shall ensure that lawful and adequate provision shall be made whereby each Warrant Holder shall thereafter
continue to have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares issuable upon exercise of the Warrants held by such Warrant Holder, the kind and amount of
securities, cash or other property of the acquiring, surviving or successor entity (“Acquirer”), as the case 

  
 7 

 
may be, resulting from such Corporate Reorganization, which a Warrant Holder of the shares deliverable upon exercise of this Warrant would have been entitled in such Corporate Reorganization if
the right to purchase the shares hereunder had been exercised immediately prior to such Corporate Reorganization. In any such case, appropriate provision shall be made with respect to the rights and interests of each Warrant Holder to the end that
the provisions hereof (including, without limitation, provision for adjustment of the Warrant Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares or other securities thereafter deliverable upon
the exercise thereof. The Company shall not effect any such Corporate Reorganization unless prior to or simultaneously with the consummation thereof the successor corporation resulting from such consolidation or merger, or the corporation purchasing
or otherwise acquiring such assets or other appropriate corporation or entity shall assume by written instrument, reasonably deemed by the board of directors of the Company and the Requisite Holders to be satisfactory in form and substance, the
obligation to deliver to the holder of the Warrants, at the last address of such holder appearing on the books of the Company, such shares of stock, property or other securities, as, in accordance with the foregoing provisions, such holder may be
entitled to purchase, and the other obligations under these Warrants. The provisions of this Section 5(d) shall similarly apply to successive Corporate Reorganizations. 

(e)    Adjustment Rules.  

(i)    Any adjustments pursuant to this Section 5 shall be made successively whenever any event
referred to herein shall occur, except that, notwithstanding any other provision of this Section 5, no adjustment shall be made to the number of Warrant Shares to be delivered to the Warrant Holder (or to the Exercise
Price) if such adjustment represents less than 1% of the number of Warrant Shares previously required to be so delivered, but any lesser adjustment shall be carried forward and shall be made at the time and together with, the next subsequent
adjustment which together with any adjustments so carried forward shall amount to 1% or more of the number of Warrant Shares to be so delivered. 

(ii)    No adjustments shall be made pursuant to this Section 5 in respect of the issuance of
Warrant Shares upon exercise of the Warrant; 
 (iii)    If the Company shall take a record of the holders of its Shares
for any purpose referred to in this Section 5, then (x) such record date shall be deemed to be the date of the issuance, sale, distribution or grant in question and (y) if the Company shall legally abandon such action prior to
effecting such action, no adjustment shall be made pursuant to this Section 5 in respect of such action. 

(iv)    In computing adjustments under this Section 5, (A) fractional interests in Shares shall
be taken into account to the nearest one-thousandth of a Share, and (B) calculations of the Exercise Price shall be carried to the nearest one-thousandth of one
cent. 
 (f)    Proceedings Prior to Any Action Requiring Adjustment. As a condition precedent to the taking of
any action which would require an adjustment pursuant to this Section 5, the Company shall take any action which may be necessary, including obtaining regulatory approvals or exemptions, in order that the Company may
thereafter validly and legally issue as fully paid and nonassessable all Shares which the Warrant Holder is entitled to receive upon exercise of the Warrant. 

(g)    Notice of Adjustment. Not less than twenty (20) days prior to the record date or effective date, as the
case may be, of any action which requires or might require an adjustment or readjustment pursuant to this Section 5, the Company shall give notice to the Warrant Holder of such event, describing such event in reasonable
detail and specifying the record date or effective date, as the case may be, and, if determinable, the required adjustment and computation thereof. If the required adjustment is not determinable as the time of such notice, the Company shall give
notice to the Warrant Holder of such 

  
 8 

 
adjustment and computation as soon as reasonably practicable after such adjustment becomes determinable. The Company will, upon the written request at any time of the Warrant Holder, furnish to
such holder a like report setting forth the Exercise Price at the time in effect and showing in reasonable detail how it was calculated. 

(h)    Subsequent Warrants. Irrespective of any adjustments in the Exercise Price or the number of Warrant Shares
issuable upon exercise of this Warrant, any successor or replacement warrants issued theretofore or thereafter may continue to express the same Exercise Price per Share and number and kind of Warrant Shares as are stated in this Warrant. 

(i)    Disputes. Any dispute which arises between the Warrant Holder and the Company with respect to the
calculation of the adjusted Exercise Price or Warrant Shares issuable upon exercise shall be determined by the independent auditors of the Company, and such determination shall be binding upon the Company and the holders of the Warrants and the
Warrant Shares if made in good faith and without manifest error. 
 (j)    Other Actions Affecting Shares.
 
 (i)    Equitable Equivalent. In case any event shall occur as to which the provisions of this
Section 5 set forth above hereof are not strictly applicable but the failure to make any adjustment would not, in the opinion of the Warrant Holder, fairly protect the purchase rights represented by this Warrant in
accordance with the essential intent and principles of this Section 5, then, in each such case, at the request of the Warrant Holder, the Company shall appoint, at the Company’s expense, a firm of independent
investment bankers of recognized national standing (which shall be completely independent of the Company and shall be satisfactory to the holder or the Requisite Holders), which shall give their opinion upon the adjustment, if any, on a basis
consistent with the essential intent and principles established in this Section 5, necessary to preserve, without dilution, the purchase rights represented by this Warrant. Upon receipt of such opinion, the Company will
promptly mail a copy thereof to the holder of this Warrant and shall make the adjustments described therein. 

(ii)    No Avoidance. The Company shall not, by amendment of its certificate of incorporation or by-laws or through any consolidation, merger, reorganization, transfer of assets, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any
of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of this Warrant
against dilution or other impairment as if the holder was a shareholder of the Company entitled to the benefit of fiduciary duties afforded to shareholders under Delaware law. 

(k)    Adjustment of Par Value. If for any reason (including the operation of the adjustment provisions set forth
in this Warrant), the Exercise Price on any date of exercise of this Warrant shall not be lawful and adequate consideration for the issuance of the relevant Warrant Shares, then the Company shall take such steps as are necessary (including the
amendment of its certificate of incorporation so as to reduce the par value of the Shares) to cause such Exercise Price to be adequate and lawful consideration on the date the payment thereof is due, but if the Company shall fail to take such steps,
then the Company acknowledges that the Warrant Holder shall have been damaged by the Company in an amount equal to an amount, which, when added to the total Exercise Price for the relevant Warrant Shares, would equal lawful and adequate
consideration for the issuance of such Warrant Shares, and the Company irrevocably agrees that if the Warrant Holder shall then forgive the right to recover such damages from the Company, such forgiveness shall constitute, and Company shall accept
such forgiveness as, additional lawful consideration for the issuance of the relevant Warrant Shares. 

  
 9 

 (l)    Appraisal.  

(i)    If the Requisite Holders shall, for any reason whatsoever, disagree with the Company’s determination of the
Appraised Value of a Share, then such holders shall by notice to the Company (an “Appraisal Notice”) given within sixty (60) days after the Company notifies the holders of such determination, elect to dispute such
determination, and such dispute shall be resolved as set forth in clause (ii) of this Section. 
 (ii)    The
Company shall within ten (10) days after an Appraisal Notice shall have been given, engage an independent investment bank of national repute (the “Appraiser”) selected by the Requisite Holders and retained pursuant to an
engagement letter between the Company and the Appraiser with respect to such valuation in form and substance reasonably acceptable to Requisite Holders, to make an independent determination of the Appraised Value of a Share; such value shall be
determined without deduction for (a) liquidity considerations, (b) minority shareholder status, or (c) any liquidation or other preference or any right of redemption in favor of any other equity securities of the Company. The costs of
engagement of such investment bank for any such determination of Appraised Value shall be paid by the Company. 

(m)    Adjustments for Diluting Issuances. Without duplication of any adjustment otherwise provided for in this
Section 5, the number of shares of common stock issuable upon conversion of the Shares shall be subject to anti-dilution adjustment from time to time in the manner set forth in the Company’s Articles or Certificate of Incorporation as if
the Shares were issued and outstanding on and as of the date of any such required adjustment; provided, however, that for purposes of clarification, there shall be no duplicative anti-dilution adjustment as a result of this provision. 

Section 6.    Registration Rights and Extension of Expiration Date. The Warrant Holder is entitled to the
benefit of certain registration rights with respect to the Warrant Shares as provided in the Amended and Restated Investors’ Rights Agreement, dated as of March 14, 2016, by and among the Company and the investors party thereto (as amended
from time to time including pursuant to that certain Amendment No. 2 to Amended and Restated Investors’ Rights Agreement, dated as of May 20, 2019, by and among the Company, the investors party thereto and the Warrant Holder, the
“Investors’ Rights Agreement”), and any subsequent holder hereof shall be entitled to such rights to the extent provided in the Investors’ Rights Agreement. If the Company fails to cause
any registration statement covering “Registrable Securities” (as that term is defined in the Investors’ Rights Agreement) to be declared effective prior to the applicable dates set forth therein, or if any of the events specified in
Section 1.2(c)(v) or Section 1.5 of the Investors’ Rights Agreement occurs, and the resulting period during which the Company is not required to effect or maintain the effectiveness of a registration statement (whether alone, or in
combination with any other such period) (the “Blackout Period”) continues for more than 30 days in any 12 month period, or for more than a total of 90 days, then the Expiration Date of this Warrant shall be extended one day
for each day beyond the 30-day or 90-day limits, as the case may be, that the Blackout Period continues. 

Section 7.    Transfer of Warrant. The Warrant Holder upon transfer of the Warrant must deliver to the Company
a duly executed Warrant Assignment in the form of Exhibit B and upon surrender of this Warrant to the Company, the Company shall execute and deliver a new Warrant with appropriate changes to reflect such Assignment, in the name or names of
the assignee or assignees specified in the Warrant Assignment or other instrument of assignment and, if the Warrant Holder’s entire interest is not being transferred or assigned, in the name of the Warrant Holder, and upon the Company’s
execution and delivery of such new Warrant, this Warrant shall promptly be cancelled; and provided that any assignee shall have all of the rights of an Initial Holder hereunder. The Warrant Holder shall pay any transfer tax imposed in
connection with such assignment (if any). Any transfer or exchange of this Warrant shall be 

  
 10 

 
without charge to the Warrant Holder (except as provided above with respect to transfer taxes, if any) and any new Warrant issued shall be dated the date hereof. 

Section 8.    Assistance in Disposition of Warrant or Warrant Shares. Notwithstanding any other provision
herein, in the event that it becomes unlawful for the Warrant Holder to continue to hold the Warrant, in whole or in part, or some or all of the Shares held by it, or restrictions are imposed on any the Warrant Holder by any statute, regulation or
governmental authority which, in the judgment of the Warrant Holder, make it unduly burdensome to continue to hold the Warrant or such Shares, the Warrant Holder may sell or otherwise dispose of the Warrant (subject to the restrictions on transfer
provided in Section 7) or its Shares, and the Company agrees to provide reasonable assistance to the Warrant Holder in disposing of the Warrant and such Shares in a prompt and orderly manner and, at the request of the Warrant Holder, to provide
(and authorize the Warrant Holder to provide) financial and other information concerning the Company to any prospective purchaser of the Warrant or Shares owned by the Warrant Holder, provided that in each case each such prospective purchaser shall
be subject to customary obligations of confidentiality. 
 Section 9.    Identity of Transfer Agent. The
transfer agent for the Common Stock is Wilson Sonsini Goodrich & Rosati, P.C. Upon the appointment of any subsequent transfer agent for the Shares, the Company will mail to the Warrant Holder a statement setting forth the name and address
of such transfer agent. 
 Section 10.    Covenants. The Company agrees that: 

(a)    Information. So long as this Warrant remains outstanding or any Initial Holder holds any Warrant Shares, the
Company will deliver to the Warrant Holder (or Initial Holder): 
 (i)    as soon as practicable, but in any event
within sixty (60) days after the end of each fiscal year of the Company, an unaudited income statement for such fiscal year, an unaudited balance sheet of the Company and statement of stockholders’ equity as of the end of such year, an
unaudited statement of cash flows for such year, and a comparison between the actual amounts as of and for such fiscal year, the comparable amounts for the prior year and the comparable amounts included in the budget and business plan of the Company
for such year, and containing an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, such year end financial reports to be in reasonable detail, all such financial
statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”); 

(ii)    as soon as practicable, but in any event within one hundred fifty (150) days after the end of each fiscal
year of the Company, an income statement for such fiscal year, a balance sheet of the Company and statement of stockholders’ equity as of the end of such year, a statement of cash flows for such year, and a comparison between the actual amounts
as of and for such fiscal year, the comparable amounts for the prior year and the comparable amounts included in the budget and business plan of the Company for such year, and containing an explanation of any material differences between such
amounts and a schedule as to the sources and applications of funds for such year, such year end financial reports to be in reasonable detail, all such financial statements prepared in accordance with GAAP and audited and certified by independent
public accountants of nationally recognized standing selected by the Company; 
 (iii)    as soon as practicable, but in
any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, an unaudited income statement, statement of cash flows for such fiscal quarter and an unaudited balance sheet
and a statement of stockholders’ equity as of the end of such fiscal quarter, and a comparison between the actual amounts as of and for such quarter, the comparable amounts for the corresponding quarter of the prior year and the

  
 11 

 
comparable amounts included in the budget and business plan of the Company for such quarter, with an explanation of any material differences between such amounts and a schedule as to the sources
and applications of funds for such quarter, all such financial statements prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments
and (ii) not contain all notes thereto that may be required in accordance with GAAP); 
 (iv)    within forty-five
(45) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet and statement of stockholders’ equity as of the end of such month, all prepared in accordance with
GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(v)    as soon as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year, a
budget and business plan for the next fiscal year, approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements and statements of cash flows for such months and, as soon as prepared, any other
budgets or revised budgets prepared by the Company; 
 (vi)    with respect to the financial statements called for in
subsections (ii) and (iii) of this Section 10(a), an instrument executed by the Chief Financial Officer or President of the Company certifying that such financials were prepared in accordance with GAAP consistently applied with prior
practice for earlier periods (with the exception of footnotes that may be required by GAAP) and fairly present the financial condition of the Company and its results of operation for the period specified, subject to year end audit adjustment; and

 (vii)    such other information relating to the financial condition, business or corporate affairs of the Company as
a Warrant Holder may from time to time reasonably request, provided, however, that the Company shall not be obligated under this subsection (vii) or any other subsection of Section 10(a) to provide information that (i) it deems in
good faith to be a trade secret or similar confidential information (unless such similar confidential information is covered by an enforceable confidentiality agreement), (ii) the disclosure of which would adversely affect the attorney-client
privilege between the Company and its counsel or (iii) would be received by a Warrant Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or holder of more than ten percent (10%) of the outstanding
capital stock of a competitor. Each Warrant Holder acknowledges that the information received by them pursuant to this Section 10(a) may be confidential and subject to customary obligations of confidentiality; and 

(viii)    if, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company,
then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

The financial information covenants set forth in this Section 10(a) shall terminate upon the initial public offering of the
Company’s securities. 
 (b)    Maintenance of Business. The Company (i) will and will cause each of
its Subsidiaries to, continue to engage in the business that the Company and its Subsidiaries are engaged in as of the date hereof and the business activities substantially related thereto, (ii) will not, and will not permit any of its
Subsidiaries to, expand into any other lines of business except those lines of business in which they are engaged in as of the date hereof, and as substantially related thereto, and (iii) will preserve, renew, and keep in full force and effect,
and will, and will cause each of its Subsidiaries to, preserve, renew, and keep 

  
 12 

 
in full force and effect, its existence as a corporation and all material rights, privileges, and franchises necessary or desirable in the customary conduct of business, and (iv) will not,
and will not permit any of its Subsidiaries to, consolidate with or merge with or into any other Person or take any action in furtherance thereof. 

(c)    [Reserved]. 

(d)    Securities Filings; Rules 144 & 144A. The Company will (i) file any reports required to be filed by
it under the Securities Act, the Exchange Act or the rules and regulations adopted by the Commission thereunder, (ii) use its commercially reasonable efforts to cooperate with the Warrant Holder and each holder of Warrant Shares in supplying
such information concerning the Company as may be necessary for the Warrant Holder or holder of Warrant Shares to complete and file any information reporting forms currently or hereafter required by the Commission as a condition to the availability
of an exemption from the Securities Act for the sale of any Warrants or Warrant Shares, (iii) take such further action as the Warrant Holder may reasonably request to the extent required from time to time to enable the Warrant Holder to sell
Warrant Shares without restriction and without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 or 144A under the Securities Act, as such Rules may be amended from time to time, or any similar rule
or regulation hereafter adopted by the Commission, and (iv) upon the request of the Warrant Holder, deliver to the Warrant Holder a written statement as to whether it has complied with such reporting requirements; provided that this
subsection (d) shall not require the Company to make any filing under the Securities Act or Exchange Act which the Company is not otherwise obligated to make. 

(e)    Obtaining of Governmental Approvals and Stock Exchange Listings. The Company will, at its own expense,
(i) obtain and keep effective any and all permits, consents and approvals of governmental agencies and authorities which may from time to time be required of the Company in order to satisfy its obligations hereunder, and (ii) take all
action which may be necessary so that the Warrant Shares, immediately upon their issuance upon the exercise of the Warrants, will be listed on each securities exchange, if any, on which the Shares are then listed. 

(f)    Inspection and Access. So long as this Warrant remains outstanding or any Holder holds any Warrant Shares,
the Company shall permit any authorized representatives designated by the Warrant Holder (or Initial Holder) to visit and inspect any of the properties of the Company and its Subsidiaries, including its and their books of account, and to discuss its
and their affairs, finances and accounts with its and their officers, all at such times as the Warrant Holder (or Initial Holder) may reasonably request. 

(g)    Notices Of Corporate Action. In the event of: 

(i)    any taking by the Company of a record of the holders of any class of securities for the purpose of determining the
holders thereof who are entitled to receive any distribution, or any right to subscribe for, purchase or otherwise acquire any Shares or any other securities or property, or to receive any other right, or 

(ii)    any capital reorganization of the Company, any reclassification or recapitalization of the capital stock of the
Company, any consolidation or merger involving the Company and any other Person or any transfer of all or substantially all the assets of the Company to any other Person, or any Corporate Reorganization, or 

(iii)    any voluntary or involuntary dissolution, liquidation or winding- up of the Company, or 

  
 13 

 (iv)    any issuance of any Shares, convertible security or option by
the Company, other than (x) under the Company’s equity incentive plan or (y) any Shares issued upon conversion or exercise thereof, 

the Company will mail to the Warrant Holder a notice specifying (i) the date or expected date on which any such record is to be taken for
the purpose of such dividend, distribution or right, and the amount and character of such dividend, distribution or right, (ii) the date or expected date on which any such reorganization, reclassification, recapitalization, consolidation,
merger, transfer, dissolution, liquidation or winding-up is to take place, (iii) the time, if any such time is to be fixed, as of which the holders of record of Shares (or other securities under
Section 5(b)) shall be entitled to exchange their Shares (or other securities under Section 5(b)) for the securities or other property deliverable upon such reorganization, reclassification, recapitalization, consolidation, merger,
transfer, dissolution, liquidation or winding-up and a description in reasonable detail of the transaction and (iv) the date of such issuance, together with a description of the security so issued and the
consideration received by the Company therefor. Such notice shall be mailed at least twenty (20) days prior to the date therein specified. 

Section 11.    Lost, Mutilated or Missing Warrants. Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of any Warrant, and, in the case of loss, theft or destruction, upon receipt of indemnification satisfactory to the Company (in the case of an Initial Holder its unsecured, unbonded
agreement of indemnity or affidavit of loss shall be sufficient) or, in the case of mutilation, upon surrender and cancellation of the mutilated Warrant, the Company shall execute and deliver a new Warrant of like tenor and representing the right to
purchase the same aggregate number of Warrant Shares. 
 Section 12.    Waivers; Amendments. Any provision
of this Warrant may be amended or waived with (but only with) the written consent of the Company and the Requisite Holders; provided that no such amendment or waiver shall, without the written consent of the Company and the Warrant Holder,
(a) change the number of Warrant Shares issuable upon exercise of the Warrant or the Exercise Price, (b) shorten the Expiration Date, or (c) amend, modify or waive the provisions of this Section or the definition of “Requisite
Holders.” Any amendment or waiver effected in compliance with this Section shall be binding upon the Company and the Warrant Holder. The Company shall give prompt notice to the Warrant Holder of any amendment or waiver effected in compliance
with this Section. No failure or delay of the Company or the Warrant Holder in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereon or the exercise of any other right or power. No notice or demand on the Company in any case shall entitle the Company to any other or future
notice or demand in similar or other circumstances. The rights and remedies of the Company and the Warrant Holder hereunder are cumulative and not exclusive of any rights or remedies which it would otherwise have. 

Section 13.    Miscellaneous. 

(a)    Shareholder Rights. The Warrant shall not entitle any Warrant Holder, prior to the exercise of the Warrant,
to any voting rights as a shareholder of the Company. 
 (b)    Expenses. The Company shall pay all reasonable
expenses of the Warrant Holder, including reasonable fees and disbursements of counsel, in connection with the preparation of the Warrant, any waiver or consent hereunder or any amendment or modification hereof (regardless of whether the same
becomes effective), or the enforcement of the provisions hereof; provided that the Company shall not be required to pay any expenses of the Warrant Holder arising solely in connection with a transfer of the Warrant. 

  
 14 

 (c)    Successors and Assigns. All the provisions of this Warrant
by or for the benefit of the Company or the Warrant Holder shall bind and inure to the benefit of their respective successors and assigns. 

(d)    Severability. In case any one or more of the provisions contained in this Warrant shall be invalid, illegal
or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby. The parties shall endeavor in good faith negotiations to replace the
invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions. 

(e)    Notices. Any notice or other communication hereunder shall be in writing and shall be sufficient if sent by
first-class mail or courier, postage prepaid, and addressed as follows: (a) if to the Company, addressed to the Company at its address for notices as set forth below its signature hereon or any other address as the Company may hereafter notify
to the Warrant Holder and (b) if to the Warrant Holder, addressed to such address as the Warrant Holder may hereafter from time to time notify to the Company for the purposes of notice hereunder. 

(f)    Equitable Remedies. Without limiting the rights of the Company and the Warrant Holder to pursue all other
legal and equitable rights available to such party for the other parties’ failure to perform its obligations hereunder, the Company and the Warrant Holder each hereto acknowledge and agree that the remedy at law for any failure to perform any
obligations hereunder would be inadequate and that each shall be entitled to specific performance, injunctive relief or other equitable remedies in the event of any such failure. 

(g)    Continued Effect. Rights and benefits conferred on the holders of Warrant Shares pursuant to the provisions
hereof (including Section 6) shall continue to inure to the benefit of, and shall be enforceable by, such holders, notwithstanding the surrender of the Warrant to, and its cancellation by, the Company upon the full or
partial exercise or repurchase hereof. 
 (h)    Confidentiality. The Warrant Holder agrees to keep confidential
any proprietary information relating to the Company delivered by the Company hereunder; provided that nothing herein shall prevent the Warrant Holder from disc losing such information: (i) to any holder of Warrants or Warrant Shares,
(ii) to any Affiliate of any holder of Warrants or Warrant Shares or any actual or potential transferee of the rights or obligations hereunder that agrees to be bound by this Section 13(h), (iii) upon order, subpoena,
or other process of any court or administrative agency or otherwise required by law, (iv) upon the request or demand of any regulatory agency or authority having jurisdiction over such party, (v) which has been publicly disclosed,
(vi) which has been obtained from any Person that is not a party hereto or an affiliate of any such party without an accompanying duty of confidentiality and, to the knowledge of the Warrant Holder, without a breach of such Person’s
obligations of confidentiality, (vii) in connection with the exercise of any remedy, or the resolution of any dispute hereunder (viii) to the legal counsel or certified public accountants for any holder of Warrants or Warrant Shares, or
(ix) as otherwise expressly contemplated by this Warrant. 
 (i)    Governing Law. THIS WARRANT SHALL BE
CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE INTERNAL LAWS OF THE STATE OF NEW YORK, EXCEPT AS OTHERWISE REQUIRED BY MANDATORY PROVISIONS OF LAW. 

(j)    Section Headings. The section headings used herein are for convenience of reference only and shall not be
construed in any way to affect the interpretation of any provisions of the Warrant. 

  
 15 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized signatory as of the day and year first above written. 
  

			
	ACUTUS MEDICAL, INC., a Delaware corporation
		
	By:	 	
                     
                   

	Name:	 	
	Title:	 	
	
	 Address for Notices:
  

2210 Faraday Ave. Suite 100
 Carlsbad, CA 92008

[Attn:
                            ]
  

[Telephone: (    )    -    ]

[Facsimile: (    )    -    ]

  
 [Signature Page to
Warrant] 

 Exhibit A to Warrant 

 Exhibit B to Warrant

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]